ArticleEJNMMI research2015
Neurotensin receptors in pancreatic ductal carcinomas.
Article in EJNMMI research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Synthesis and Evaluation ofACS omega · 2026Article
- Article
- Reshaping [Pharmaceutics · 2025Article
- Recent Advances in Small Molecular PET Tracers for Pancreatic Cancer Diagnosis: Preclinical Stage.Mini reviews in medicinal chemistry · 2025Review
- Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway.American journal of cancer research · 2024Article
- Side-Chain Modified [International journal of molecular sciences · 2023Article
- Toward Stability Enhancement of NTSPharmaceutics · 2023Article
- NTSR1 glycosylation and MMP dependent cleavage generate three distinct forms of the protein.Scientific reports · 2023Article
- Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2.ACS omega · 2023Article
- Neurotensin analogs by fluoroglycosylation at NScientific reports · 2022Article
- Expression of neurotensin receptor-1 (NTSBreast cancer research and treatment · 2021Article
- Sweetening Pharmaceutical Radiochemistry byPharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?International journal of molecular sciences · 2021Review
- Clinical Perspectives of Theranostics.Molecules (Basel, Switzerland) · 2021Review
- Neurotensin receptor 1 signaling promotes pancreatic cancer progression.Molecular oncology · 2021Article
- Neurotensin pathway in digestive cancers and clinical applications: an overview.Cell death & disease · 2020Review
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2020Review
- GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.British journal of pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe frequent expression of neurotensin receptors (NT-R) in primaries of pancreatic ductal carcinomas has triggered the development of radioactive neurotensin analogs for possible in vivo targeting of these tumors. However, the complete lack of information regarding NT-R in liver metastases of pancreatic cancer and pancreatic intraepithelial neoplasia (PanIN) makes an in vitro study of NT-R in these tissues indispensable.
methodsUsing in vitro receptor autoradiography with (125)I-[Tyr(3)]-neurotensin, NT-R were investigated in 18 primaries and 23 liver metastases of pancreatic ductal carcinomas as well as in 19 PanIN lesions.
resultsWe report here that 13 of 18 ductal carcinoma primaries and 14 of 23 liver metastases expressed NT-R. Moreover, none of the six PanIN 1B cases expressed NT-R, while two of six PanIN 2 and five of seven PanIN 3 expressed NT-R. Binding was fully displaced by the type 1 NT-R-selective antagonist SR48692, indicating that the NT-R in the tumors are of the type 1 NT-R subtype.
conclusionsThese in vitro data extend the currently available information on NT-R in invasive and non-invasive pancreatic ductal tumors. They suggest that type 1 NT-R may be a novel, specific marker of PanIN of higher degree. The high expression of NT-R in primaries and metastases of invasive cancer strongly support the need to develop radioactive neurotensin analogs for the diagnosis and therapy of this tumor type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.